APP and early-onset autosomal dominant Alzheimer disease: To determine whether TUDCA exerts protective effects on cognitive decline in Alzheimer’s disease, we administered TUDCA to APP/PS1 mice beginning at 6 months of age, when early pathological features start to emerge.